Pure Global AI
NCT06385730Not yet recruiting

Neoadjuvant PD-1 Blockade for Elderly Esophageal Squamous Cell Carcinoma (BLESS)

Neoadjuvant PD-1 Blockade (Toripalimab) Monotherapy for Elderly Patients With Locally Advanced Resectable Esophageal Squamous Cell Carcinoma: a Phase II Trial
Shanghai Chest HospitalPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Esophageal Cancer
Drug/Device/Intervention
neoadjuvant anti-PD-1
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Shanghai Chest Hospital
Location
Shanghai, China
Timeline & enrollment
Phase
Phase 2
Start date
May 01, 2024
End date
May 01, 2027
Enrollment
60 participants
Primary outcome

MPR rate

Summary

The investigators will conduct a prospective phase 2 study to evaluate the efficacy and
 safety of neoadjuvant PD-1 blockade monotherapy with toripalimab in elderly patients with
 locally advanced resectable esophageal squamous cell carcinoma (ESCC).

ICD-10 classifications
Carcinoma in situ: OesophagusMalignant neoplasm of oesophagusMalignant neoplasm: Middle third of oesophagusMalignant neoplasm: Overlapping lesion of oesophagusMalignant neoplasm: Upper third of oesophagus
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06385730
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06385730 through Pure Global AI's free database. This Phase 2 trial is sponsored by Shanghai Chest Hospital and is currently Not yet recruiting. The study focuses on Esophageal Cancer. Target enrollment is 60 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.